Hematology NewsR-CHOP matched more intense regimens for overall survival in high-risk, untreated DLBCLJuly 10, 2017Aggressive LymphomasLymphoma & Plasma Cell Disorders
Hematology NewsTazemetostat active against follicular lymphoma with EZH2 mutationJuly 7, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesNivolumab for long-term treatment of cHL after auto-HSCTJuly 7, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Hematology TimesFDA clears use of reagents to detect hematopoietic neoplasiaJuly 3, 2017CythemiasAnemiaLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersMultiple MyelomaAggressive Lymphomas
Hematology TimesDrug granted PRIME access as treatment for DLBCLJuly 2, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCAR T-cell therapy shows early promise in DLBCLJune 30, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesLess is more in PET-negative, advanced HLJune 28, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Hematology TimesCSF p-Tau predicts neurocognitive sequelae in survivors of childhood cancerJune 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersPediatricsALLNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesBrentuximab meets phase 3 primary endpoint in frontline advanced HLJune 27, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
Hematology TimesNew SC rituximab formulation approved, reduces administration timeJune 24, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsTwofer drug blocks SYK/JAK pathways in advanced NHLJune 23, 2017CLLLymphoma & Plasma Cell DisordersAggressive LymphomasFollicular Lymphoma
Hematology TimesChemo-free triplet produces ‘favorable’ results in advanced diseaseJune 23, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology NewsFDA approves rituximab + hyaluronidase human for FL, DLBCL, and CLLJune 22, 2017CLLAggressive LymphomasLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersFollicular Lymphoma
Hematology TimesInhibitor elicits responses in heavily pretreated FL, DLBCLJune 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesNew frontline treatments needed for Hodgkin lymphomaJune 22, 2017Lymphoma & Plasma Cell DisordersHodgkin LymphomaAggressive Lymphomas
